Short-term effect of fenofibrate on C-reactive protein: A meta-analysis of randomized controlled trials

Diabetology and Metabolic Syndrome

Volumn 3, Issue 1, 2011, Pages

  Ye, Jiatao ^a   Kiage, James N ^a   Arnett, Donna K ^a   Bartolucci, Alfred A ^a   Kabagambe, Edmond K ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

clinical trials; CRP; fenofibrate; meta analysis; randomized; short term

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CERIVASTATIN; FENOFIBRATE; NICOTINIC ACID; PLACEBO; SIMVASTATIN;

ARTICLE; BEHAVIOR; BODY WEIGHT; CONCENTRATION (PARAMETERS); DATA BASE; DATA EXTRACTION; DIET; DRUG EFFECT; DRUG EFFICACY; HUMAN; META ANALYSIS; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS;

EID: 80053173357     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-3-24     Document Type: Article

References (46)

1. Inflammation biomarkers and risk of all-cause mortality in the reasons for geographic and racial differences in stroke cohort. Kabagambe EK, Judd SE, Howard VJ, Zakai NA, Jenny NS, Hsieh M, Warnock DG, Cushman M, American Journal of Epidemiology 2011 174 284 292 10.1093/aje/kwr085 21685411
2. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, Hutchinson WL, Pepys MB, Circulation 1999 99 237 242 9892589 (Pubitemid 29056365)
3. C-reactive protein and all-cause mortality in a large hospital-based cohort. Marsik C, Kazemi-Shirazi L, Schickbauer T, Winkler S, Joukhadar C, Wagner OF, Endler G, Clin Chem. United States 2008 54 343 349 (Pubitemid 351302621)
4. Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease - a perspective. Kones R, Drug Des Devel Ther 2010 4 383 413 21267417
5. Inflammation biomarkers and near-term death in older men. Jenny NS, Yanez ND, Psaty BM, Kuller LH, Hirsch CH, Tracy RP, Am J Epidemiol 2007 165 684 695 10.1093/aje/kwk057 17215383 (Pubitemid 46348379)
6. Association between laboratory markers and presence of coronary artery disease. Kincl V, Panovsky R, Meluzin J, Semenka J, Groch L, Tomcikova D, Jarkovsky J, Dusek L, Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2010 154 227 233 21048808
7. High-sensitivity C-reactive protein: an independent risk factor for left ventricular hypertrophy in patients with lupus nephritis. Shi B, Ni Z, Cai H, Zhang M, Mou S, Wang Q, Cao L, Yu Z, Yan Y, Qian J, J Biomed Biotechnol 2010 2010 373 426
8. Human CRP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart disease. Brull DJ, Serrano N, Zito F, Jones L, Montgomery HE, Rumley A, Sharma P, Lowe GD, World MJ, Humphries SE, Hingorani AD, Arterioscler Thromb Vasc Biol. United States 2003 23 2063 2069 (Pubitemid 37433201)
9. Air pollution and inflammation (interleukin-6, C-reactive protein, fibrinogen) in myocardial infarction survivors. Ruckerl R, Greven S, Ljungman P, Aalto P, Antoniades C, Bellander T, Berglind N, Chrysohoou C, Forastiere F, Jacquemin B, et al. Environ Health Perspect 2007 115 1072 1080 10.1289/ehp.10021 17637925 (Pubitemid 47317075)
10. Blood lipids and adipokines concentrations during a 6-month nutritional and physical activity intervention for metabolic syndrome treatment. Dutheil F, Lesourd B, Courteix D, Chapier R, Dore E, Lac G, Lipids Health Dis. England 2010 9 148 10.1186/1476-511X-9-148
11. Fruit and vegetable consumption and proinflammatory gene expression from peripheral blood mononuclear cells in young adults: a translational study. Hermsdorff HH, Zulet MA, Puchau B, Martinez JA, Nutr Metab (Lond). England 2010 7 42 10.1186/1743-7075-7-42
12. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Ridker PM, Rifai N, Lowenthal SP, Circulation 2001 103 1191 1193 11238259 (Pubitemid 32221338)
13. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. Muhlestein JB, May HT, Jensen JR, Horne BD, Lanman RB, Lavasani F, Wolfert RL, Pearson RR, Yannicelli HD, Anderson JL, J Am Coll Cardiol 2006 48 396 401 10.1016/j.jacc.2006.05.009 16843192
14. Monocyte release of tumor necrosis factor-alpha and interleukin-1beta in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates. Okopien B, Krysiak R, Kowalski J, Madej A, Belowski D, Zielinski M, Herman ZS, J Cardiovasc Pharmacol. United States 2005 46 377 386 (Pubitemid 41262842)
15. Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1500 mg. Wi J, Kim JY, Park S, Kang SM, Jang Y, Chung N, Shim WH, Cho SY, Lee SH, Atherosclerosis 2010 213 235 240 10.1016/j.atherosclerosis. 2010.08.068 20855072
16. Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus. Hiukka A, Westerbacka J, Leinonen ES, Watanabe H, Wiklund O, Hulten LM, Salonen JT, Tuomainen TP, Yki-Jarvinen H, Keech AC, Taskinen MR, J Am Coll Cardiol 2008 52 2190 2197 10.1016/j.jacc.2008.09.049 19095138
17. Microvascular endothelial function in subjects with Type 2 diabetes and the effect of lipid-lowering therapy. Fegan PG, Shore AC, Mawson D, Tooke JE, MacLeod KM, Diabet Med. England 2005 22 1670 1676 10.1111/j.1464-5491.2005. 01719.x (Pubitemid 43046466)
18. Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. Hogue JC, Lamarche B, Tremblay AJ, Bergeron J, Gagne C, Couture P, Metabolism. United States 2008 57 380 386 (Pubitemid 351178728)
19. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Higgins JPT, Green S, 2011 http://www.cochrane-handbook.org
20. Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. Bax L, Yu L-M, Ikeda N, Tsuruta H, Moons K, BMC Medical Research Methodology 2006 6 50 10.1186/1471-2288-6-50 17038197 (Pubitemid 44662384)
21. MIX 1.7: Comprehensive free soft ware for metaanalysis of causal research data. Bax L, http://www.meta-analysis-made-easy.com/ (Last accessed: August 16, 2011)
22. A fail-safe N for effect size in meta-analysis. Orwin RG, Journal of Educational Statistics 1983 8 157 159
23. Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men-a nuclear magnetic resonance study. Ikewaki K, Tohyama J, Nakata Y, Wakikawa T, Kido T, Mochizuki S, J Atheroscler Thromb. Japan 2004 11 278 285 10.5551/jat.11.278
24. Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia. Pruski M, Krysiak R, Okopien B, Diabetes Care. United States 2009 32 1421 1424
25. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Koh KK, Han SH, Quon MJ, Yeal Ahn J, Shin EK, Diabetes Care. United States 2005 28 1419 1424 (Pubitemid 40756707)
26. The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidaemic hypertensive patients. Coban E, Ozdogan M, Yazicioglu G, Sari R, Int J Clin Pract. England 2005 59 415 418 10.1111/j.1368-5031.2005. 00428.x (Pubitemid 40467884)
27. Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels. Phuntuwate W, Suthisisang C, Koanantakul B, Chaloeiphap P, Mackness B, Mackness M, Atherosclerosis. Ireland 2008 196 122 128
28. Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension. Zhu S, Su G, Meng QH, Clin Chem. United States 2006 52 2036 2042 (Pubitemid 44658204)
29. A comparative study of anti-inflammatory and antidyslipidemic effects of fenofibrate and statins on rheumatoid arthritis. Goto M, Mod Rheumatol 2010 20 238 243 10.1007/s10165-009-0261-2 20143119
30. Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter, comparative study. Ansquer JC, Bekaert I, Guy M, Hanefeld M, Simon A, Am J Cardiovasc Drugs. New Zealand 2009 9 91 101
31. Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, D'Angelo A, Cicero AF, Curr Med Res Opin 2009 25 1973 1983 10.1185/03007990903073159 19555253
32. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. Okopien B, Krysiak R, Herman ZS, J Clin Endocrinol Metab. United States 2006 91 1770 1778
33. [The anti-inflammatory and antioxidants effects of micronized fenofibrate in patients with visceral obesity and dyslipidemia]. Broncel M, Cieslak D, Koter-Michalak M, Duchnowicz P, Mackiewicz K, Chojnowska-Jezierska J, Pol Merkur Lekarski 2006 20 547 550 16875159 (Pubitemid 43805997)
34. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, Taskinen MR, Simes RJ, Tse D, Williamson E, et al. Lancet. England 2007 370 1687 1697 10.1016/S0140-6736(07) 61607-9 (Pubitemid 350100775)
35. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, et al. Lancet 2009 373 1175 1182 10.1016/S0140-6736(09)60447-5 19329177
36. Prior statin use, intracranial hemorrhage, and outcome after intra-arterial thrombolysis for acute ischemic stroke. Meier N, Nedeltchev K, Brekenfeld C, Galimanis A, Fischer U, Findling O, Remonda L, Schroth G, Mattle HP, Arnold M, Stroke. United States 2009 40 1729 1737
37. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J, Atherosclerosis 2006 189 19 30 10.1016/j.atherosclerosis.2006.02.012 16530201 (Pubitemid 44468073)
38. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, et al. Lancet 2010 375 735 742 10.1016/S0140-6736(09)61965-6 20167359
39. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, Genuth S, Gerstein HC, Ginsberg HN, Goff DC Jr, et al. Am J Cardiol 2007 99 21i 33i 17599422
40. Effects of fenofibrate on C-reactive protein levels in hypertriglyceridemic patients. Kim CJ, J Cardiovasc Pharmacol. United States 2006 47 758 763
41. Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia. Undas A, Celinska-Lowenhoff M, Domagala TB, Iwaniec T, Dropinski J, Lowenhoff T, Szczeklik A, Thromb Haemost. Germany 2005 94 193 199 (Pubitemid 40974724)
42. Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors. Sebestjen M, Keber I, Zegura B, Simcic S, Bozic M, Fressart MM, Stegnar M, Thromb Haemost. Germany 2004 92 1129 1135 (Pubitemid 39545539)
43. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. Wang TD, Chen WJ, Lin JW, Cheng CC, Chen MF, Lee YT, Atherosclerosis. Ireland 2003 170 315 323
44. Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes. Krysiak R, Gdula-Dymek A, Bachowski R, Okopien B, Diabetes Care. United States 2010 33 2266 2270
45. Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients. Rosenson RS, Obesity (Silver Spring). United States 2009 17 504 509
46. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome. Belfort R, Berria R, Cornell J, Cusi K, J Clin Endocrinol Metab. United States 2010 95 829 836